Recommended Topic Related To:

Novolog Mix 70-30

"Nov. 15, 2012 -- The number of people diagnosed with diabetes in the U.S. jumped by 50% or more in 42 states and by more than 100% in 18 of those states in just under two decades, according to the latest snapshot from the CDC.

NovoLog Mix 70/30

Indications
Dosage
How Supplied

INDICATIONS

NovoLog Mix 70/30 (insulin aspart protamine and insulin aspart (rdna origin)) is an insulin analog indicated to improve glycemic control in patients with diabetes mellitus.

Important Limitations of Use:

In premix insulins, such as Novolog Mix 70/30 (insulin aspart protamine and insulin aspart (rdna origin)) , the proportions of rapid acting and long acting insulins are fixed and do not allow for basal versus prandial dose adjustments.

DOSAGE AND ADMINISTRATION

Dosing

NovoLog Mix 70/30 (insulin aspart protamine and insulin aspart (rdna origin)) is an insulin analog with an earlier onset and intermediate duration of action in comparison to the basal human insulin premix. The addition of protamine to the rapid-acting aspart insulin analog (NovoLog) results in insulin activity that is 30% short-acting and 70% long-acting. NovoLog Mix 70/30 (insulin aspart protamine and insulin aspart (rdna origin)) is typically dosed on a twice-daily basis (with each dose intended to cover 2 meals or a meal and a snack). The dosage of NovoLog Mix 70/30 (insulin aspart protamine and insulin aspart (rdna origin)) must be individualized. The written prescription for NovoLog Mix 70/30 (insulin aspart protamine and insulin aspart (rdna origin)) should include the full name, to avoid confusion with NovoLog (insulin aspart) and Novolin 70/30 (human premix).

NovoLog Mix 70/30 (insulin aspart protamine and insulin aspart (rdna origin)) should appear uniformly white and cloudy. Do not use it if it looks clear or if it contains solid particles. NovoLog Mix 70/30 (insulin aspart protamine and insulin aspart (rdna origin)) should not be used after the printed expiration date.

NovoLog Mix 70/30 (insulin aspart protamine and insulin aspart (rdna origin)) should be administered by subcutaneous injection in the abdominal region, buttocks, thigh, or upper arm. NovoLog Mix 70/30 (insulin aspart protamine and insulin aspart (rdna origin)) has a faster onset of action than human insulin premix 70/30 and should be dosed within 15 minutes before meal initiation for patients with type 1 diabetes. For patients with type 2 diabetes, dosing should occur within 15 minutes before or after meal initiation. Injection sites should be rotated within the same region to reduce the risk of lipodystrophy. As with all insulins, the duration of action may vary according to the dose, injection site, blood flow, temperature, and level of physical activity.

NovoLog Mix 70/30 (insulin aspart protamine and insulin aspart (rdna origin)) should not be administered intravenously or used in insulin infusion pumps. Dose regimens of NovoLog Mix 70/30 (insulin aspart protamine and insulin aspart (rdna origin)) will vary among patients and should be determined by the health care professional familiar with the patient's recommended glucose treatment goals, metabolic needs, eating habits, and other lifestyle variables.

Resuspension

NovoLog Mix 70/30 (insulin aspart protamine and insulin aspart (rdna origin)) is a suspension that must be visually inspected and resuspended immediately before use.

The NovoLog Mix 70/30 (insulin aspart protamine and insulin aspart (rdna origin)) vial should be rolled gently in your hands in a horizontal position 10 times to mix it. The rolling procedure must be repeated until the suspension appears uniformly white and cloudy. Inject immediately. Resuspension is easier when the insulin has reached room temperature.

The NovoLog Mix 70/30 (insulin aspart protamine and insulin aspart (rdna origin)) FlexPen should be rolled 10 times gently between your hands in a horizontal position. Thereafter, turn the NovoLog Mix 70/30 (insulin aspart protamine and insulin aspart (rdna origin)) FlexPen upside down so that the glass ball moves from one end of the reservoir to the other. Do this at least 10 times. The rolling and turning procedure must be repeated until the suspension appears uniformly white and cloudy. Inject immediately. Before each subsequent injection, turn the disposable NovoLog Mix 70/30 (insulin aspart protamine and insulin aspart (rdna origin)) FlexPen upside down so that the glass ball moves from one end of the reservoir to the other at least 10 times and until the suspension appears uniformly white and cloudy. Inject immediately.

HOW SUPPLIED

Dosage Forms And Strengths

NovoLog Mix 70/30 (insulin aspart protamine and insulin aspart (rdna origin)) is available in the following package sizes: each presentation contains 100 units of insulin aspart per mL (U-100).

  • 10 mL vials
  • 3 mL NovoLog Mix 70/30 (insulin aspart protamine and insulin aspart (rdna origin)) FlexPen

Storage Handling

NovoLog Mix 70/30 (insulin aspart protamine and insulin aspart (rdna origin)) is available in the following package sizes: each presentation contains 100 Units of insulin aspart per mL (U-100).

10 mL vials NDC 0169-3685-12
3 mL NovoLog Mix 70/30 (insulin aspart protamine and insulin aspart (rdna origin)) FlexPen NDC 0169-3696-19

NovoLog Mix 70/30 (insulin aspart protamine and insulin aspart (rdna origin)) vials and NovoLog Mix 70/30 (insulin aspart protamine and insulin aspart (rdna origin)) FlexPen are latex free.

Recommended Storage

Unused NovoLog Mix 70/30 (insulin aspart protamine and insulin aspart (rdna origin)) should be stored in a refrigerator between 2°C and 8°C (36°F to 46°F). Do not store in the freezer or directly adjacent to the refrigerator cooling element. Do not freeze NovoLog Mix 70/30 (insulin aspart protamine and insulin aspart (rdna origin)) or use NovoLog Mix 70/30 (insulin aspart protamine and insulin aspart (rdna origin)) if it has been frozen.

Vials: After initial use, a vial may be kept at temperatures below 30°C (86°F) for up to 28 days, but should not be exposed to excessive heat or sunlight. Open vials may be refrigerated.

Unpunctured vials can be used until the expiration date printed on the label if they are stored in a refrigerator. Keep unused vials in the carton so they will stay clean and protected from light.

NovoLog Mix 70/30 (insulin aspart protamine and insulin aspart (rdna origin)) FlexPen: Once a NovoLog Mix 70/30 (insulin aspart protamine and insulin aspart (rdna origin)) FlexPen is punctured, it should be kept at temperatures below 30°C (86°F) for up to 14 days, but should not be exposed to excessive heat or sunlight. A NovoLog Mix 70/30 (insulin aspart protamine and insulin aspart (rdna origin)) FlexPen in use must NOT be stored in the refrigerator. Keep the disposable NovoLog Mix 70/30 FlexPen away from direct heat and sunlight. An unpunctured NovoLog Mix 70/30 FlexPen can be used until the expiration date printed on the label if they are stored in a refrigerator. Keep any unused NovoLog Mix 70/30 (insulin aspart protamine and insulin aspart (rdna origin)) FlexPen in the carton so it will stay clean and protected from light.

These storage conditions are summarized in the following table:

  Not in-use (unopened) Room Temperature (below 30°C [86°F]) Not in-use (unopened) Refrigerated (2°C - 8°C [36°F- 46°F]) In-use (opened) Room Temperature (below 30°C [86°F])
10 mL vial 28 days Until expiration date 28 days (refrigerated/room temperature)
3 ml NovoLog Mix 70/30 FlexPen 14 days Until expiration date 14 days (Do not refrigerate)

Manufactured by: Novo Nordisk A/S,DK-2880 Bagsvaerd, Denmark. For information about NovoLog Mix 70/30 (insulin aspart protamine and insulin aspart (rdna origin)) contact: Novo Nordisk Inc., Princeton, New Jersey 08540, 1-800-727-6500. www.novonordisk-us.com

Last reviewed on RxList: 6/9/2010
This monograph has been modified to include the generic and brand name in many instances.

Indications
Dosage
How Supplied
A A A

NovoLog Mix 70/30 - User Reviews

NovoLog Mix 70/30 User Reviews

Now you can gain knowledge and insight about a drug treatment with Patient Discussions.

Here is a collection of user reviews for the medication NovoLog Mix 70/30 sorted by most helpful. Patient Discussions FAQs

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Diabetes

Find tips and advances in treatment.